Christophe Guignabert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6484679/publications.pdf

Version: 2024-02-01

167 papers	10,762 citations	34105 52 h-index	34986 98 g-index
178 all docs	178 docs citations	178 times ranked	9626 citing authors

#	Article	IF	Citations
1	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. European Respiratory Journal, 2019, 53, 1801887.	6.7	776
2	Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 165-175.	4.5	708
3	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548
4	Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D4-D12.	2.8	465
5	An antiproliferative BMP-2/PPARÎ³/apoE axis in human and murine SMCs and its role in pulmonary hypertension. Journal of Clinical Investigation, 2008, 118, 1846-1857.	8.2	314
6	Dysregulated Reninâ€“Angiotensinâ€“Aldosterone System Contributes to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 780-789.	5.6	309
7	Right Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension. Circulation, 2013, 128, 2016-2025.	1.6	294
8	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. European Respiratory Journal, 2020, 56, 2001634.	6.7	284
9	Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension. Circulation, 2006, 113, 1857-1864.	1.6	257
10	Pulmonary arterial remodeling induced by a Th2 immune response. Journal of Experimental Medicine, 2008, 205, 361-372.	8.5	234
11	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	8.2	208
12	Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats. Circulation, 2005, 111, 2812-2819.	1.6	200
13	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscleâ€“Like Cells in Pulmonary Hypertension. Circulation, 2014, 129, 1586-1597.	1.6	178
14	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. Journal of Clinical Investigation, 2009, 119, 512-523.	8.2	177
15	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. European Respiratory Review, 2013, 22, 543-551.	7.1	172
16	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
17	Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension. Circulation Research, 2006, 98, 1323-1330.	4.5	170
18	RhoA and Rho Kinase Activation in Human Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1151-1158.	5.6	165

#	Article	IF	Citations
19	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 983-997.	5.6	144
20	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1332-1340.	1.6	141
21	New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Chest, 2015, 147, 529-537.	0.8	140
22	Tie2-mediated loss of peroxisome proliferator-activated receptor-Î³ in mice causes PDGF receptor-Î²-dependent pulmonary arterial muscularization. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L1082-L1090.	2.9	136
23	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745.	6.7	136
24	Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 311-322.	2.9	125
25	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. Journal of Clinical Investigation, 2018, 128, 1956-1970.	8.2	125
26	The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy. Nature Reviews Cardiology, 2021, 18, 565-580.	13.7	115
27	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595.	5.6	113
28	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 895-904.	6.7	110
29	Pathology and Pathobiology of Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 551-559.	2.1	100
30	Optimising experimental research in respiratory diseases: an ERS statement. European Respiratory Journal, 2018, 51, 1702133.	6.7	98
31	Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation, 2013, 128, 512-523.	1.6	97
32	Developmental expression of LC3Î± and Î²: Absence of fibronectin or autophagy phenotype in LC3Î² knockout mice. Developmental Dynamics, 2008, 237, 187-195.	1.8	93
33	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nature Genetics, 2013, 45, 518-521.	21.4	93
34	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217.	6.7	89
35	A Critical Role for p130^{Cas} in the Progression of Pulmonary Hypertension in Humans and Rodents. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 666-676.	5.6	85
36	Neurohormonal Axis in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 14-19.	5.6	85

#	Article	IF	Citations
37	Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 910-924.	1.6	83
38	Contractile Dysfunction of Left Ventricular Cardiomyocytes in Patients With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2014, 64, 28-37.	2.8	82
39	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circulation Research, 2019, 124, 846-855.	4.5	81
40	Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22Î±â€targeted overexpression of the serotonin transporter. FASEB Journal, 2009, 23, 4135-4147.	0.5	80
41	S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phosphoâ€“Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. Circulation Research, 2009, 105, 639-647.	4.5	80
42	Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1410-1420.	5.6	77
43	Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. Drug Discovery Today, 2019, 24, 428-439.	6.4	74
44	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. Cardiovascular Research, 2020, 116, 885-893.	3.8	70
45	Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. European Respiratory Journal, 2009, 34, 1100-1110.	6.7	68
46	BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	6.7	68
47	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Annals of the Rheumatic Diseases, 2017, 76, 1931-1940.	0.9	67
48	Targeting transforming growth factor-Î² receptors in pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002341.	6.7	67
49	Protein Changes Contributing to Right Ventricular Cardiomyocyte Diastolic Dysfunction in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2014, 3, e000716.	3.7	65
50	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. Chest, 2016, 149, 1482-1493.	0.8	63
51	Leptin signalling system as a target for pulmonary arterial hypertension therapy. European Respiratory Journal, 2015, 45, 1066-1080.	6.7	62
52	Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2018, 11, e002087.	3.6	62
53	SM22Î±-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis. Development (Cambridge), 2008, 135, 2981-2991.	2.5	58
54	Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword?. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 714-724.	2.1	54

#	Article	IF	Citations
55	PPARÎ³ Interaction with UBR5/ATMIN Promotes DNA Repair to Maintain Endothelial Homeostasis. Cell Reports, 2019, 26, 1333-1343.e7.	6.4	54
56	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Cardiovascular Research, 2020, 116, 686-697.	3.8	54
57	Effect of doxycycline on sulfur mustard-induced respiratory lesions in guinea pigs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 289, L67-L74.	2.9	53
58	Cellular microparticles in the pathogenesis of pulmonary hypertension. European Respiratory Journal, 2013, 42, 272-279.	6.7	51
59	Dasatinib increases endothelial permeability leading to pleural effusion. European Respiratory Journal, 2018, 51, 1701096.	6.7	50
60	Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229.	6.7	50
61	Copper Dependence of Angioproliferation in Pulmonary Arterial Hypertension in Rats and Humans. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 582-591.	2.9	46
62	Dual Role for Plasminogen Activator Inhibitor Type 1 as Soluble and as Matricellular Regulator of Epithelial Alveolar Cell Wound Healing. American Journal of Pathology, 2006, 169, 1624-1632.	3.8	45
63	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. European Respiratory Journal, 2016, 48, 1517-1519.	6.7	44
64	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 766-782.	2.4	44
65	Smooth Muscle Protein 22Î±â€“Mediated Patchy Deletion of Bmpr1a Impairs Cardiac Contractility but Protects Against Pulmonary Vascular Remodeling. Circulation Research, 2008, 102, 380-388.	4.5	43
66	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881.	0.8	43
67	Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 267-279.	2.5	42
68	T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Research and Therapy, 2018, 20, 197.	3.5	40
69	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2014, 15, 65.	3.6	38
70	Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension. Cardiovascular Research, 2019, 115, 432-439.	3.8	38
71	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilanceâ€“pharmacodynamic study. European Respiratory Journal, 2019, 53, 1802472.	6.7	37
72	Expression of TLR9 in tumorâ€infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. International Journal of Cancer, 2014, 134, 765-777.	5.1	35

#	Article	IF	Citations
73	Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. Expert Opinion on Therapeutic Targets, 2017, 21, 181-190.	3.4	34
74	ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. European Respiratory Journal, 2018, 51, 1800848.	6.7	34
75	Pathology and Pathobiology of Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 571-584.	2.1	33
76	Recurrence of Pulmonary Emphysema in an Î±-1 Proteinase Inhibitor-deficient Lung Transplant Recipient. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 811-814.	5.6	31
77	Renal Denervation Reduces PulmonaryÂVascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension. JACC Basic To Translational Science, 2017, 2, 22-35.	4.1	31
78	Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 342-355.	5.6	30
79	An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. Nature Communications, 2021, 12, 1720.	12.8	30
80	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. European Respiratory Journal, 2020, 56, 2000279.	6.7	28
81	Serum and pulmonary uric acid in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000332.	6.7	28
82	Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. Reproductive Toxicology, 2015, 56, 45-51.	2.9	27
83	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2015, 15, 13-26.	2.2	27
84	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. Cardiovascular Research, 2022, 118, 1805-1820.	3.8	26
85	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Chest, 2022, 161, 219-231.	0.8	26
86	Vascular-wall remodeling of 3 human bypass vessels: Organ culture and smooth muscle cell properties. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 651-658.	0.8	25
87	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. European Respiratory Journal, 2019, 54, 1802400.	6.7	25
88	Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancerâ€like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure. Pulmonary Circulation, 2019, 9, 1-15.	1.7	23
89	The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient. Cells, 2020, 9, 1422.	4.1	23
90	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovascular Research, 2021, 117, 1391-1401.	3.8	23

#	Article	IF	Citations
91	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal, 2019, 33, 3670-3679.	0.5	22
92	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. European Respiratory Review, 2018, 27, 180004.	7.1	21
93	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 4105.	4.1	21
94	Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension. Frontiers in Physiology, 2018, 9, 555.	2.8	21
95	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. Journal of Medicinal Chemistry, 2018, 61, 2725-2736.	6.4	20
96	New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis. Circulation Research, 2022, 130, 1365-1381.	4.5	20
97	Inhibition of Transforming Growth Factor Î² Worsens Elastin Degradation in a Murine Model of Kawasaki Disease. American Journal of Pathology, 2011, 178, 1210-1220.	3.8	19
98	The Thousand Faces of Leptin in the Lung. Chest, 2021, 159, 239-248.	0.8	18
99	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2209-2221.	5.6	17
100	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Annals of Cardiothoracic Surgery, 2022, 11, 106-119.	1.7	17
101	Purinergic Dysfunction in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2020, 9, e017404.	3.7	16
102	Altered TGFÎ²/SMAD Signaling in Human and Rat Models of Pulmonary Hypertension: An Old Target Needs Attention. Cells, 2021, 10, 84.	4.1	16
103	New targets for pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2017, 23, 377-385.	2.6	16
104	Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed. European Respiratory Journal, 2013, 41, 3-4.	6.7	15
105	A genome-wide association analysis identifies PDE1A|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population. Oncotarget, 2017, 8, 74917-74926.	1.8	15
106	Lysyl oxidaseâ€"a possible role in systemic sclerosisâ€"associated pulmonary hypertension: a multicentre study. Rheumatology, 2019, 58, 1547-1555.	1.9	15
107	Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H604-H612.	3.2	13
108	Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1-L9.	2.9	13

#	Article	IF	Citations
109	Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling. Thorax, 2021, 76, 326-334.	5.6	13
110	Driving Role of Interleukinâ€2â€“Related Regulatory <scp>CD4</scp>+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 1387-1398.	5.6	13
111	Angiomatoid fibrous histiocytoma of the pulmonary artery: a multidisciplinary discussion. Histopathology, 2014, 65, 278-282.	2.9	12
112	Functional interaction between PDGFÎ² and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L445-L455.	2.9	12
113	Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease. European Respiratory Journal, 2020, 55, 1900169.	6.7	12
114	Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort. Journal of Heart and Lung Transplantation, 2022, 41, 445-457.	0.6	12
115	Pulmonary Alveolar Proteinosis Revealing a Telomerase Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 402-404.	5.6	11
116	Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. European Respiratory Journal, 2014, 43, 641-643.	6.7	11
117	The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. Lancet Rheumatology, The, 2021, 3, e149-e159.	3.9	11
118	Telomere Maintenance Is a Critical Determinant in the Physiopathology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2015, 66, 1942-1943.	2.8	9
119	Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2020, 9, 1248.	2.4	8
120	Smooth muscle Rac1 contributes to pulmonary hypertension. British Journal of Pharmacology, 2022, 179, 3418-3429.	5.4	8
121	Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension. Handbook of Experimental Pharmacology, 2013, , 409-436.	1.8	7
122	CRISPR/Cas9-mediated inactivation of the phosphatase activity of soluble epoxide hydrolase prevents obesity and cardiac ischemic injury. Journal of Advanced Research, 2023, 43, 163-174.	9.5	7
123	Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. British Journal of Clinical Pharmacology, 2022, 88, 5227-5237.	2.4	7
124	Update in Pulmonary Vascular Disease 2016 and 2017. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 13-23.	5.6	6
125	Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension. Handbook of Experimental Pharmacology, 2013, 218, 409-436.	1.8	6
126	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. Arthritis Research and Therapy, 2022, 24, 13.	3.5	6

#	Article	IF	Citations
127	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2015, 46, 1211-1214.	6.7	5
128	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. International Journal of Clinical Pharmacy, 2018, 40, 790-794.	2.1	5
129	Plateletâ€Derived Growth Factor Receptor Type Î± Activation Drives Pulmonary Vascular Remodeling Via Progenitor Cell Proliferation and Induces Pulmonary Hypertension. Journal of the American Heart Association, 2022, 11, e023021.	3.7	5
130	Response to the article â€œSorafenib as a potential strategy for refractory pulmonary arterial hypertensionâ€• Pulmonary Pharmacology and Therapeutics, 2017, 45, 11-12.	2.6	3
131	Response by Guignabert et al to Letter Regarding Article, â€œSelective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertensionâ€• Circulation Research, 2019, 124, e82-e83.	4.5	2
132	Dendritic Cells in Pulmonary Hypertension: Foot Soldiers or Hidden Enemies?. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 551-552.	2.9	2
133	Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?. Metabolites, 2021, 11, 784.	2.9	2
134	Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	2.9	2
135	The Therapeutic Potential Of The Renin-Angiotensin-Aldosteron System In Idiopathic Pulmonary Arterial Hypertension. , 2012, , .		1
136	Editorial: Molecular Mechanisms in Pulmonary Hypertension and Right Ventricle Dysfunction. Frontiers in Physiology, 2018, 9, 1777.	2.8	1
137	Pulmonary arterial remodeling induced by a Th2 immune response. Journal of Cell Biology, 2008, 180, i9-i9.	5.2	1
138	Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model. , 2018, , .		1
139	Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic BMPR2 mutation carriers (DELPHI-2 Study). , 2019, , .		1
140	Different tryptophan-kynurenine metabolism profiles in human pulmonary arterial hypertension and animal models of pulmonary hypertension. European Heart Journal, 2020, 41, .	2.2	1
141	Reply: The Reninâ€“Angiotensin System in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1139-1140.	5.6	0
142	Pulmonary hypertension associated with neurofibromatosis type 2. Pulmonary Circulation, 2021, 11, 1-4.	1.7	0
143	Interplay Between Serotonin Transporter Signaling and Voltage-Gated Potassium Channel (Kv) 1.5 Expression. , 0, , .		0
144	Pathophysiology and Treatment of Pulmonary Arterial Hypertension. , 2015, , 949-974.		0

#	Article	IF	Citations
145	Hematopoietic Stem Cells and Chronic Hypoxia-Induced Pulmonary Vascular Remodelling. Pancreatic Islet Biology, 2015, , 241-256.	0.3	0
146	Time-resolved study of endothelial shear-responsiveness in pulmonary arterial hypertension. , 2015, , .		0
147	Endothelial-derived MIF contributes to pulmonary endothelial cell proliferation in human pulmonary arterial hypertension. , 2015, , .		0
148	IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension. , 2015, , .		0
149	Changes in red blood cell membrane structure in pulmonary arterial hypertension. , 2016, , .		0
150	Uric acid causes excessive pulmonary arterial smooth muscle cell proliferationviaURATv1 upregulation in pulmonary arterial hypertension. , 2016, , .		0
151	Dasatinib increases endothelial permeability leading to pleural effusion. , 2017, , .		0
152	Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model. , 2017, , .		0
153	Contribution of BMP9 to Pulmonary Arterial Hypertension. , 2017, , .		0
154	OP0089â€…Abatacept is effective in experimental digestive and lung tissue fibrosis. , 2018, , .		0
155	Pathophysiological mechanisms in pulmonary hypertension. , 2018, , 2487-2489.		0
156	Pulmonary vascular remodeling mediated by ADORA2B in pulmonary artery smooth muscle cells. , 2018, , .		0
157	Late Breaking Abstract - MIF inhibition in a murine model of bleomycin-induced lung fibrosis. , 2018, , .		0
158	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Asvide, 2021, 8, 298-298.	0.0	0
159	Dysfunction and Restoration of Endothelial Cell Communications in Pulmonary Arterial Hypertension: Therapeutic Implications. , 2020, , 147-155.		0
160	Role of Connexin 43 increased expression in pulmonary arterial hyperreactivityinduced by the nerve growth factor NGF. , 2021, , .		0
161	NGF induces pulmonary arterial hyperreactivity through connexin 43 increased expression. , 2020, , .		0
162	Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment?. , 2020, , .		0

#	Article	IF	Citations
163	Role of c-Abelson in the loss of genome integrity in endothelial cells in pulmonary arterial hypertension. , 2020, , .		0
164	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodeling in experimental pulmonary hypertension. , 2020, , .		0
165	Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models. , 2020, , .		0
166	Lower plasma melatonin levels predict worse long-term survival in pulmonary arterial hypertension. European Heart Journal, 2020, 41, .	2.2	0
167	Erythrocytes are altered in pulmonary arterial hypertension. European Respiratory Journal, 0, , 2200506.	6.7	0